TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8612381
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) 2 hours after terfenadine for 7 days
Study: 6749189
Drug: Anticholinergic agent
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic agent (atropine methonitrate)
Study: 6749189
Drug: Adrenergic agent
Normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic agent (salbutamol)
Study: 6749189
Drug: Anticholinergic agent
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic agent first
Study: 6749189
Drug: Adrenergic agent
Normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic agent first
Study: 26821876
Drug: Bilateral transversus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral transversus abdominis plane block using 21 ml of 0.25% bupivacaine and 4.0 mg dexamethasone
Study: 26821876
Drug: Parenteral opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral opioids alone (sham block with 21 ml 0.9% saline)
Study: 22517769
Drug: ROSE-010 100
Normalized name: Rose Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSE-010 100 μg
Study: 22517769
Drug: ROSE-010 300
Normalized name: Rose Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSE-010 300 μg
Study: 22517769
Drug: ROSE-010 30
Normalized name: Rose Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSE-010 30 μg
Study: 22517769
Drug: ROSE-010 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSE-010 (all doses)
Study: 12236441
Drug: 7.6% carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.6% carbohydrate‐electrolyte solution (CES)
Study: 11016338
Drug: Pneumoperitoneum (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumoperitoneum (1200 mL of air injected under the right hemidiaphragm)
Study: 1462894
Drug: Recombinant tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue‐type plasminogen activator (rTPA), 1 mg/kg body weight (maximum 100 mg) during 4 hours, in addition to aspirin, heparin, and beta‐blockade
Study: 6376484
Drug: Isocarboxazid (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocarboxazid (active medication)
Study: 30670279
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (10 days of oral vitamin A)
Study: 27121115
Drug: High-selenium lentils
Normalized name: HIGH SELENIUM YEAST
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-selenium lentils (65 g per day for 6 months)
Study: 27121115
Drug: Low-selenium lentils
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-selenium lentils (65 g per day for 6 months)
Study: 24520782
Drug: Hydrocortisone edema
Normalized name: hydrocortisone Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone edema solution
Study: 16398599
Drug: Soy +
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy + probiotic capsules
Study: 16398599
Drug: Milk +
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk + probiotic capsules
Study: 12087922
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg tablet (test formulation)
Study: 12087922
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg tablet (reference formulation)
Study: 10617243
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg simvastatin/d for 6 weeks
Study: 10617243
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg simvastatin/d for 6 weeks
Study: 8538903
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg/die (Group A, n = 10)
Study: 8538903
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/die (Group B, n = 20)
Study: 8538903
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/die + Nitrendipine 20 mg/die (Group C, n = 10)
Study: 31233281
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg plus MTX
Study: 23114828
Drug: FP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP with the conventional rigid bar splinting the implants
Study: 17146370
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) regimens including > or =3 agents
Study: 9586422
Drug: Bromocriptine (Br)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (Br) 2.5 mg po at time -60
Study: 8575494
Drug: Etretinate 25
Normalized name: etretinate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate 25 mg orally each day
Study: 2773665
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion after ibuprofen
Study: 2773665
Drug: Nitroprusside infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside infusion after ibuprofen
Study: 19690306
Drug: Nursing-led psychoeducational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing-led psychoeducational intervention (Project ENABLE) consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161)
Study: 9119635
Drug: BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment (150 mg Pasteur BCG per instillation, 6-week induction course, single maintenance doses for 2 years)
Study: 9119635
Drug: Epirubicin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin treatment (50 mg per instillation, early instillation on postoperative day 2, followed by 4 weekly treatments and 10 monthly treatments for 2 years)
Study: 9119635
Drug: BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG treatment in patients with stage T1 and grade 3 tumours
Study: 1394824
Drug: Intravenous methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methotrexate, vinblastine, Adriamycin, and cisplatin (M‐VAC)
Study: 1394824
Drug: Factors analyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors analyzed included performance status (PS), M category, and dose of drugs
Study: 29341404
Drug: canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: canagliflozin 100 mg
Study: 29341404
Drug: canagliflozin 200
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: canagliflozin 200 mg
Study: 24915612
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a 180 μg/week
Study: 2243896
Drug: Methysergide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide (4 mg p.o.)
Study: 8981385
Drug: Metergoline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline (4 mg p.o.)
Study: 2243896
Drug: MCPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCPP (0.5 mg/kg p.o.)
Study: 445772
Drug: Persistent medical
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent medical therapy
Study: 31562005
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B birth dose (HepB- BD)
Study: 23921271
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 µg/kg/min after a loading dose of 12 µg/kg)
Study: 8193735
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg o.d.
Study: 8193735
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg o.d. as basic antihypertensive treatment
Study: 3989697
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tablet formulation
Study: 3989697
Drug: syrup formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: syrup formulation
Study: 3989697
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tablet formulation with different inactive excipients
Study: 29461870
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (PR2.3.1)
Study: 25630582
Drug: Topical spot-on
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spot-on formulation containing 6.76% w/v fipronil + 50.48% w/v permethrin
Study: 18565817
Drug: Selenium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium therapy (L-seleno-methionine 2 x 100 microg/day for one year)
Study: 18565817
Drug: Selenium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium therapy
Study: 15717211
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of sarizotan
Study: 3404814
Drug: Arginine HCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine HCl, 250 mg/kg infused over 30 minutes
Study: 3404814
Drug: Indomethacin, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 150 mg
Study: 3160915
Drug: Ibuprofen, 800
Normalized name: Ibuprofen, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 800 mg
Study: 3404814
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cyclooxygenase inhibitors)
Study: 3404814
Drug: Indomethacin, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 150 mg before second infusion of arginine
Study: 21949643
Drug: Standard antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiretroviral therapy (ART)
Study: 21310502
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT); 39 patients/44 feet, twice per week for 6 treatments
Study: 21310502
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT); 38 patients/40 feet, daily for 20 treatments
Study: 15606437
Drug: Cetirizine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine at 0.25 mg kg(‐1) twice daily for 18 months
Study: 15606437
Drug: Levocetirizine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 0.125 mg kg(‐1) twice daily
Study: 29625591
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment (ART) with an age-appropriate stimulation program, updated at 3 monthly intervals through the first year of life.
Study: 26517283
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) factor VIII (200 IU kg‐1 day‐1)
Study: 26517283
Drug: Low-dose (LD)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (LD) factor VIII (50 IU kg‐1 3× per week)
Study: 22168137
Drug: Weekly TM-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly TM-based feedback with goal setting
Study: 22168137
Drug: Weekly TM-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly TM-based drinking assessments without feedback
Study: 19660970
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of Hormone Replacement Therapy (HRT)
Study: 9927002
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (500 mg, 2 times a day for 48 h)
Study: 342594
Drug: Naftidrofuryl (Praxilene)
Normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (Praxilene) 300 mg per day
Study: 28479852
Drug: DWP05195 (10-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP05195 (10-600 mg single dose; 100-400 mg once daily for 8 days)
Study: 28479852
Drug: DWP05195 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP05195 (multiple doses)
Study: 28479852
Drug: DWP05195 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP05195 (up to 600 mg single dose; 400 mg multiple dose)
Study: 19384179
Drug: De novo
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De novo sirolimus-based therapy without calcineurin inhibitors
Study: 19384179
Drug: Initial use
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial use of a calcineurin inhibitor for 2 to 4 months followed by conversion to sirolimus
Study: 19384179
Drug: Late withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late withdrawal of steroids
Study: 14598251
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with Photofrin 2 mg/kg body weight, administered intravenously 2 days before intraluminal photoactivation (wavelength, 630 nm; light dose, 180 J/cm²)
Study: 8986544
Drug: Transmandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmandibular implant (TMI) with a triple bar and cantilever extensions, provided with an overdenture
Study: 8986544
Drug: Intramobile cylinder
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramobile cylinder implants (IMZ) connected by a Dolder bar, provided with an overdenture
Study: 1729935
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and placebo intravenously after induction
Study: 1729935
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Study: 1729935
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge 45 min preoperatively and placebo (normal saline) injected intravenously after induction
Study: 1729935
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Study: 29278428
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) plus G‐CSF 3 monthly plus GH daily (group A; n = 23)
Study: 29278428
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) plus G‐CSF (group B; n = 21)
Study: 29278428
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy alone (group C; n = 21)
Study: 26991619
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (initial bolus of 0.25 μg/kg and infusion of 0.25 μg/kg/min)
Study: 20346565
Drug: Bioadhesive 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive 0.2% CHX gel applied intraoperatively once after surgical removal of the third molar
Study: 20346565
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied in an identical fashion
Study: 20346565
Drug: Bioadhesive 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive 0.2% CHX gel
Study: 16259543
Drug: Olanzapine (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (6-12 mg/day) plus fluoxetine (25-50 mg/day) combination
Study: 16259543
Drug: Olanzapine (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (6-12 mg/day)
Study: 16259543
Drug: Fluoxetine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (25-50 mg/day)
Study: 16259543
Drug: Nortriptyline (25-175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (25-175 mg/day)
Study: 16259543
Drug: Olanzapine/fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/fluoxetine combination (subgroup analysis)
Study: 782888
Drug: Hyperbaric oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygenation (OHP) administered at 2.5 ATA in one or several series of daily exposure.
Study: 782888
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (control group).
Study: 25076759
Drug: Cytoflavin included
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cytoflavin included in intensive care (administered intravenously at a speed of 140 drops (7 ml) per minute within 7 days, starting from the second day post-injury).
Study: 15352968
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg po 1 h prior to surgery
Study: 15352968
Drug: Control (Placebo)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Placebo) + Ketoprofen 100 mg IV q 8 h for 24 h
Study: 8115195
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg meperidine
Study: 3136636
Drug: Class IC
Normalized name: Antiarrhythmics, class Ic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class IC agents (overall)
Study: 793706
Drug: Azathioprine, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine, 2.5 mg/kg-d
Study: 21784378
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg added to Simvastatin 40 mg (E/S40)
Study: 21784378
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg (A)
Study: 21784378
Drug: Rosuvastatin 5-10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5-10 mg (R)
Study: 17507190
Drug: Sustained-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nifedipine tablets from DiSha (test)
Study: 17507190
Drug: Sustained-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nifedipine tablets from GuoFeng (reference)
Study: 10024902
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined HRT (2 mg 17 beta‐estradiol and 1 mg norethisterone acetate administered once daily without estriol)
Study: 8002124
Drug: GP/PL mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP/PL mixture (6.25 g GP to 0.75 g PL per 100 ml of water)
Study: 8002124
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer solution (GP)
Study: 30498758
Drug: Curene 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curene 500 mg once daily
Study: 27465859
Drug: Aspirin users
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin users (32 patients)
Study: 18630533
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with western medicine (acupuncture at specific points, intramuscular injection of Vit B1 and Vit B12, oral administration of ATP)
Study: 16046716
Drug: Lyophilized grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized grape powder (LGP) 36 g for 4 weeks
Study: 12360108
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg twice daily)
Study: 12360108
Drug: Inhaled beta-agonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta-agonist salbutamol (200 microg)
Study: 6148572
Drug: Vaccine aerosol
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine aerosol given by mask at a dose of 3500 or 7000 PFU
Study: 6148572
Drug: Vaccine aerosol
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine aerosol given from a plastic bag at a dose of 7000 PFU
Study: 6148572
Drug: 11 400
Normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11 400 PFU of vaccine intradermally in two divided doses
Study: 30196837
Drug: Interferon-beta (IFNB)
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta (IFNB) treatment
Study: 30196837
Drug: No immunomodulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunomodulatory treatment
Study: 24362488
Drug: Ponesimod (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (40 mg) with combined oral contraceptive (1 mg norethisterone and 35 μg ethinyl estradiol)
Study: 24362488
Drug: Ponesimod (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (20 mg)
Study: 24362488
Drug: Ponesimod (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponesimod (40 mg)
Study: 11857045
Drug: MCT/LCT (50/50)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT/LCT (50/50) supplemented with 100 mg DL-alpha-tocopherol/day
Study: 10404024
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) (cyclic estradiol/norethisterone acetate)
Study: 7564082
Drug: OPC‐31260 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐31260 (1 mg/kg body wt)
Study: 7564082
Drug: OPC‐31260 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐31260 (low dose unspecified)
Study: 2188795
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg trazodone at night
Study: 2188795
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg dothiepin at night
Study: 6996149
Drug: Isopyrine 240
Normalized name: tisopurine
DrugBank: Tisopurine (DB13807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopyrine 240 mg plus phenylbutazone 130 mg (Tomanol)
Study: 28633773
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - 15 sessions (8 J/cm2; 830 nm)
Study: 28633773
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) - 3 sessions (2000 shocks)